Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small cell lung cancer

Chinese Medical Journal

Volumn 123, Issue 22, 2010, Pages 3200-3205

  Zhu, Yu Jia ^a   Xia, Ying ^a   Ren, Guan Jun ^a   Wang, Meng Zhao ^a   Zeng, Xuan ^a   Zhang, L ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Epidermal growth factor; Erlotinib; KRAS; Messager; Mutation; Non small cell lung cancer; Receptor; RNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MESSENGER RNA;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DNA DETERMINATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRY EYE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79251479395     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.22.005     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Bunn PA Jr. Chemotherapy for advanced non-small cell lung cancer: who, what, when, why? J Clin Oncol 2002; 20 (18 Suppl): 23S-33S.
3. Rosell R, Fossella F, Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer 2002; 38 Suppl 4: 43-49.
4. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongpraset S, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123-132.
5. Therasse P, Arbuck SG, Eisenhauer EA, Wander J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
6. Flagella M, Bui S, Zheng Z, Nguyen CT, Zhang A, Pastor L, et al. A multiplex branched DNA assay for parallel quantitative gene expression profiling. Analytical Biochemistry 2006; 352: 50-60
7. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004; 22: 3238-3247.
8. Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Mutsui K, Watanabe M, et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008; 3: 1439-1445.
9. Perng RP, Yang CH, Chen YM, Chang GC, Lin MC, Hsieh RK, et al. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 2008; 62: 78-84.
10. Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fukuoka M. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2004; 46: 247-254.
11. Florescu M, Hasan B, Seymour L, Ding K, Sheperd FA. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Thorac Oncol 2008; 3: 590-598.
12. Sasaki H, Endo K, Mizuno K, Yano M, Fukai I, Yamakawa Y, et al. EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer. Lung Cancer 2006; 51: 135-136.
13. Guan ZZ, Zhang L, Li LY, Jiang GL, Liu XY, Chu DT, et al. Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial. Cancer (Chin) 2005; 24: 980-984.
14. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-4275.
15. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
16. Schneider C, Schott-von Romer K, Gutz S, Raack B, Dierkesmann R, Laack E, et al. Biomarker analysis from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2007; 25: a7674.
17. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909.
18. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007; 13: 2890-2896.
19. Dziadziuszko R, Witta SE, Cappuzo F, Park S, Tanaka K, Danenberg PV, et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 2006; 12: 3078-3084.
20. Emery IF, Batteli C, Auclair PL, Carrier K, Hayes DM. Response to gefitinib and erlotinib in non-small cell lung cancer: a restrospective study. BMC Cancer 2009; 9: 333.
21. Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 2003; 9: 2241-2247.